Therapeutic Antibodies and Other Proteins Obtained by Molecular Display Technologies
Seiji Shibasaki and Mitsuyoshi Ueda
Affiliation: Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Minatojima, Chuo-ku, Kobe 650-8530, Japan.
Keywords: Therapeutic antibody, molecular display, phage, yeast, affibody, romiplostim, ribosome, monoclonal antibody, Fc domain, TPO
Since the approval of antibodies as therapeutic agents more than 20 years ago, a large about of research conducted by pharmaceutical companies and other institutes has been focused on the development of therapeutic antibodies. Antibody-based drugs have higher specificity and are more effective than chemical reagents in depletion of target cells, particularly diseased cells such as tumor cells, viral-infected cells, and other pathogenic cells. However, as compared to synthetic agents, they are generally more expensive and accelerating expansion of budgets on medicine. Hitherto, genetic engineering techniques, especially molecular display technology, have played an important role in the development of various active therapeutic antibodies. To reduce the expenditure associated with the production of these antibodies, the selection of candidate molecules- an upstream process must be optimized for efficiency. This review article summarizes recent representative patents related to therapeutic antibodies and molecular display techniques that have been used for their production.
Rights & PermissionsPrintExport